NCT02717325CompletedNot Applicable
Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Bayer
- Enrollment
- 10
- Primary Endpoint
- Minimal Persistent Pigment DArkening Dose (MPPD)
Study Overview
Brief Summary
To evaluate the Sun Protection Factor (SPF) efficacy on human skin.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
- •Male and female
- •Aged between 18-70 years old.
- •Good health as determined from the HRL SHF
- •Signed and dated Informed Consent Form
- •Signed and dated HIPAA Form
- •An unambiguous MED or MPPD (Minimal Persistent Pigment Darkening Dose)
Exclusion Criteria
- •Subjects on test at any other research laboratory or clinic.
- •Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
- •Pre-existing dermatologic conditions which have been diagnoses by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.
- •Pre-existing other medical conditions (e.g. adult asthma. diabetes).
- •Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
- •Treatment with antibiotics within two weeks prior to initiation of the test.
- •Chronic medication which could affect the results of the study.
- •Known pregnant or nursing women.
Arms & Interventions
BAY987517
Experimental
Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application fo test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application
Intervention: Coppertone (BAY987517) (Drug)
Outcomes
Primary Outcomes
Minimal Persistent Pigment DArkening Dose (MPPD)
Time Frame: Up to 15 minutes
Minimal Erythema Dose (MED)
Time Frame: Up to 15 minutes
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Completed
Not Applicable
18750-Sun Protection Factor AssaySunscreening AgentsNCT02741466Bayer10
Completed
Not Applicable
18751-Sun Protection Factor Assay.Sunscreening AgentsNCT02739802Bayer10
Completed
Not Applicable
18790 - Sun Protection Factor AssaySunscreening AgentNCT02695303Bayer10
Completed
Not Applicable
Sun Protection Factor Assay (SPF Assay 105/2016)Sunscreening AgentsNCT02891044Bayer12
Completed
Not Applicable
Sun Protection Factor Assay (SPF Assay 201/2016)Sunscreening AgentsNCT02930772Bayer11